Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 141.38 points (-0.8%) at 17,673 as of Friday, Jan. 23, 2015, 4:20 PM ET. The NYSE advances/declines ratio sits at 1,370 issues advancing vs. 1,694 declining with 158 unchanged.

The Diversified Services industry as a whole closed the day down 0.2% versus the S&P 500, which was down 0.5%. Top gainers within the Diversified Services industry included

Bioanalytical Systems

(

BASI

), up 3.3%,

MGT Capital Investments

(

MGT

), up 10.0%,

Cambium Learning Group

(

ABCD

), up 5.2%,

RMG Networks

(

RMGN

), up 5.4% and

Luna Innovations

(

LUNA

), up 1.8%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

RMG Networks

(

RMGN

) is one of the companies that pushed the Diversified Services industry higher today. RMG Networks was up $0.06 (5.4%) to $1.18 on light volume. Throughout the day, 11,000 shares of RMG Networks exchanged hands as compared to its average daily volume of 48,100 shares. The stock ranged in a price between $1.13-$1.19 after having opened the day at $1.13 as compared to the previous trading day's close of $1.12.

RMG Networks has a market cap of $13.6 million and is part of the services sector. Shares are down 10.4% year-to-date as of the close of trading on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close,

Cambium Learning Group

(

ABCD

) was up $0.12 (5.2%) to $2.42 on heavy volume. Throughout the day, 81,059 shares of Cambium Learning Group exchanged hands as compared to its average daily volume of 20,800 shares. The stock ranged in a price between $2.31-$2.48 after having opened the day at $2.36 as compared to the previous trading day's close of $2.30.

Cambium Learning Group, Inc. operates as an educational solutions and services company in the United States. It operates in four segments: Voyager Sopris Learning (VSL), Learning A-Z, ExploreLearning, and Kurzweil/IntelliTools. Cambium Learning Group has a market cap of $102.9 million and is part of the services sector. Shares are up 38.0% year-to-date as of the close of trading on Thursday. Currently there are no analysts who rate Cambium Learning Group a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Cambium Learning Group as a

sell

. The area that we feel has been the company's primary weakness has been its generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on ABCD go as follows:

  • This stock's share value has moved by only 13.47% over the past year. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
  • ABCD, with its decline in revenue, slightly underperformed the industry average of 5.1%. Since the same quarter one year prior, revenues slightly dropped by 4.2%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • The gross profit margin for CAMBIUM LEARNING GROUP INC is currently very high, coming in at 73.16%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 2.41% trails the industry average.
  • Net operating cash flow has significantly increased by 59.82% to $19.64 million when compared to the same quarter last year. In addition, CAMBIUM LEARNING GROUP INC has also vastly surpassed the industry average cash flow growth rate of -5.58%.
  • CAMBIUM LEARNING GROUP INC has shown improvement in its earnings for its most recently reported quarter when compared with the same quarter a year earlier. The company has demonstrated a pattern of positive earnings per share growth over the past two years. During the past fiscal year, CAMBIUM LEARNING GROUP INC continued to lose money by earning -$0.31 versus -$2.72 in the prior year.

You can view the full analysis from the report here:

Cambium Learning Group Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Bioanalytical Systems

(

BASI

) was another company that pushed the Diversified Services industry higher today. Bioanalytical Systems was up $0.07 (3.3%) to $2.17 on light volume. Throughout the day, 200 shares of Bioanalytical Systems exchanged hands as compared to its average daily volume of 5,500 shares. The stock ranged in a price between $2.10-$2.17 after having opened the day at $2.10 as compared to the previous trading day's close of $2.10.

Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in North America, the Pacific Rim, Europe, and internationally. Bioanalytical Systems has a market cap of $16.6 million and is part of the services sector. Shares are down 6.0% year-to-date as of the close of trading on Thursday. Currently there are no analysts who rate Bioanalytical Systems a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Bioanalytical Systems as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on BASI go as follows:

  • BIOANALYTICAL SYSTEMS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has suffered a declining pattern earnings per share over the past two years. During the past fiscal year, BIOANALYTICAL SYSTEMS INC swung to a loss, reporting -$0.15 versus $0.09 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Life Sciences Tools & Services industry. The net income has significantly decreased by 260.3% when compared to the same quarter one year ago, falling from $0.25 million to -$0.40 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Life Sciences Tools & Services industry and the overall market, BIOANALYTICAL SYSTEMS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The gross profit margin for BIOANALYTICAL SYSTEMS INC is currently lower than what is desirable, coming in at 34.63%. It has decreased from the same quarter the previous year. Along with this, the net profit margin of -6.29% is significantly below that of the industry average.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 31.49%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 266.66% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.

You can view the full analysis from the report here:

Bioanalytical Systems Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.